Related Experiment Video

Updated: Aug 7, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Influence of melanoma inhibitory activity on transforming growth factor-beta signaling in malignant melanoma

Tanja Rothhammer1, Anja-Katrin Bosserhoff

  • 1Institute of Pathology, University of Regensburg Medical School, Regensburg, Germany.

Melanoma Research
|July 18, 2006
PubMed

Insights

Melanoma cells evade growth inhibition by expressing Ski and Sno inhibitors. Melanoma inhibitory activity (MIA) deficiency reduces these inhibitors, revealing a MAPK/ERK pathway regulation of melanoma growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Melanoma cells resist transforming growth factor-beta (TGFbeta)-induced growth arrest.
  • This resistance is mediated by Smad (mothers against decapentaplegic homolog, Drosophila) inhibitors Ski and Sno.
  • Melanoma inhibitory activity (MIA) is implicated in melanoma progression.

Purpose of the Study:

  • To investigate the role of MIA in regulating TGFbeta-mediated growth inhibition in melanoma.
  • To elucidate the molecular mechanisms by which melanoma cells escape TGFbeta signaling.
  • To identify the signaling pathways controlling Ski and Sno expression in melanoma.

Main Methods:

  • Utilized Smad-responsive reporter constructs to assess TGFbeta signaling.
  • Analyzed the expression of TGFbeta target genes (JunB, Id-1) and Smad inhibitors (Ski, Sno).
  • Investigated the involvement of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway using MEK inhibitors.

Main Results:

  • MIA-deficient melanoma cells showed restored TGFbeta signaling and induction of TGFbeta target genes.
  • Ski and Sno expression was absent in MIA-deficient cells but present in parental cells.
  • MEK inhibition reduced Ski and Sno expression, indicating MAPK/ERK pathway regulation.

Conclusions:

  • MIA influences the expression of Ski and Sno, key repressors of TGFbeta/SMAD signaling in melanoma.
  • Ski and Sno expression in this melanoma model is regulated by the MAPK/ERK signaling cascade.
  • Targeting the MAPK/ERK pathway could be a therapeutic strategy for melanoma.

More Related Videos

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...